PhRMA Applauds USTR Special 301 Report, Urges Action on Drug IPR Through NAFTA
The Pharmaceutical Research and Manufacturers of America praised sections of the recently released 2018 Special 301 report that highlighted intellectual property concerns related to pharmaceuticals, in a statement issued April 27. “The Report highlights serious threats America’s biopharmaceutical innovators face…
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
in countries around the world, including with trading partners like Canada, Japan, Colombia and others,” it said. PhRMA had encouraged the U.S. trade representative to list South Korea, Canada and Malaysia as priority foreign countries. South Korea recently agreed to end discriminatory pricing and reimbursement policies, while USTR added Canada as a priority country and said it would conduct a review of Malaysia’s intellectual property system (see 1804270044), the trade group said. “The U.S. government should continue using all available tools, including ongoing NAFTA negotiations, to level the playing field for American innovators,” PhRMA said.